Genelux (NASDAQ:GNLX) Raised to "Hold" at Wall Street Zen

Genelux (NASDAQ:GNLX - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

Several other research firms have also weighed in on GNLX. HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Genelux in a research note on Monday, March 31st. Benchmark reduced their price objective on shares of Genelux from $25.00 to $23.00 and set a "speculative buy" rating for the company in a research note on Thursday, May 8th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $17.75.

Genelux Stock Up 15.5%

GNLX opened at $3.06 on Friday. Genelux has a fifty-two week low of $1.60 and a fifty-two week high of $5.89. The firm has a market cap of $115.47 million, a PE ratio of -3.22 and a beta of -0.49. The business has a fifty day simple moving average of $2.59 and a 200-day simple moving average of $3.07.

Genelux (NASDAQ:GNLX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.03. On average, equities research analysts anticipate that Genelux will post -0.88 EPS for the current fiscal year.

Hedge Funds Weigh In On Genelux

A number of institutional investors have recently modified their holdings of the company. Alyeska Investment Group L.P. acquired a new position in Genelux in the 1st quarter valued at $770,000. Heights Capital Management Inc. bought a new stake in Genelux during the first quarter valued at about $644,000. Woodward Diversified Capital LLC grew its position in shares of Genelux by 15.2% in the first quarter. Woodward Diversified Capital LLC now owns 1,461,113 shares of the company's stock valued at $3,945,000 after purchasing an additional 192,808 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Genelux in the first quarter valued at about $239,000. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of Genelux in the first quarter worth about $215,000. Institutional investors own 37.33% of the company's stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.